CAR-T Cell Companies Proliferate: List of CAR-T Companies Worldwide

CAR-T cell therapy is as a type of immunotherapy that teaches T cells to recognize and destroy cancer.  This article provides a list of all known CAR-T cell therapy companies worldwide. Some of the companies are developing their therapies in-house, while others have invested in, acquired, or partnered with companies developing CAR-T cell therapies. With every passing year, CAR-T cell therapies continues to be revolutionized by advancements in treatments and technologies. What is capable of being done today would have been previously unfathomable. 

Perinatal Stem Cell Society's 10th Anniversary on May 17th

Join the celebration of the Perinatal Stem Cell Society's 10th anniversary on May 17th, featuring free talks by Peter Marks, Director of FDA CBER, and 27 renowned scientists discussing perinatal stem cells and tissue. When you register for the event, you will also gain access to an additional 50+ videos from past conferences. Register now with code "BIOI" for a 25% discount before the early bird registration ends on May 2. Access Dr. Marks' presentation for FREE at this link. 

Gamida Cell Secures World’s 1st FDA Approval for an Expanded Cord Blood Cell Therapy

BOSTON, MA–Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, announced that the U.S. Food and Drug Administration (FDA) has approved Gamida Cell’s allogeneic cell therapy, Omisirge® (omidubicel-onlv), for use in adult and pediatric patients 12 years and older with hematologic malignancies planned for umbilical cord blood transplantation following myeloablative conditioning to reduce the time to neutrophil recovery and the incidence of infection.

iPSC Culture and Differentiation: The Future of Disease Modeling and Drug Discovery

The generation of induced pluripotent stem cells (iPSCs) involves technologies such as reprogramming, culturing of iPS cells, differentiation of cell types from iPSCs, cell analysis, cell engineering, and beyond. Although several firms are engaged in providing iPSC tools and technologies—such as reprogramming vectors, transfection kits, maintenance and differentiation media, immunocytochemistry, and live staining kits—it is still difficult for researchers to produce required quantities of iPSCs.

Turbocharge the Development of Scalable & Reproducible iPSC-Derived Therapies

Just one week to go until 70+ technical leaders at the forefront of iPSC process development congregate to brainstorm solutions at the 2nd Annual iPSC Manufacturing Summit. 

With the race on to develop a reproducible, reliable, safe and scalable manufacturing process – can you afford to miss out?

ImmuneBridge Raises $12M from M Ventures and Insight Partners to Advance Cord Blood-Derived NK Cell Immunotherapies

SAN FRANCISCO, CA – ImmuneBridge, a biotech company using nature’s innate intelligence to fight cancer, closed an oversubscribed $12 million seed financing co-led by global investors Insight Partners and M Ventures, the strategic, corporate venture capital arm of Merck KGaA, Darmstadt, Germany. ImmuneBridge’s expansion technology expands hematopoietic stem cells (HSCs), which are natural precursors of NK cells. HSCs are readily available via umbilical cord blood from public cord blood banks across the U.S. and globally.

PBS Biotech and denovoMATRIX Join Forces to Boost Manufacturing Processes for Cell & Gene Therapies

Camarillo, CA (April 11, 2023) – PBS Biotech, an innovative, single-use bioreactor manufacturer and process development services provider, announces its collaboration with denovoMATRIX, a leading supplier of next-gen biomimetic coating technologies. By joining forces, PBS Biotech and denovoMATRIX seek to foster xeno-free expansion and scale-up of clinical-grade mesenchymal stromal cells (MSCs) and induced pluripotent stem cells (iPSCs) for use in allogeneic and autologous cell and gene therapies. The first outcome of this collaboration is a white paper presenting the advantages in MSC manufacturing that can be achieved using their cutting-edge technologies.

New Peer-Reviewed Study Shows Promising Advances in Regenerative Medicine

Olathe, KS – Ronawk, a biotech and biofabrication company powered by the Bio-Block Universe™, is pleased to announce a groundbreaking new study titled “Tissue-mimetic culture enhances mesenchymal stem cell secretome capacity to improve regenerative activity of keratinocytes and fibroblasts in vitro” which has been published in the flagship journal, Wound Repair and Regeneration, of the Wound Healing Society.

AGS Therapeutics Unveils Ambitious R&D Pipeline, Showcasing the Potential of its Universal Delivery System for Novel Therapeutics

Paris, April 3, 2023 – AGS Therapeutics, an early-stage biotech company pioneering micro-algae extracellular vesicles (MEV) as a new delivery system for innovative therapeutic treatments, announced its initial internal research and development (R&D) pipeline. It is designed to showcase the potential of its MEVs as a new groundbreaking delivery system for bringing a wide range of payloads, including mRNA, siRNA, plasmid-DNA, antisense oligonucleotides (ASO), peptides, and proteins, to a variety of tissues and organs for treatment of a wide range of diseases.

Boston BioProducts Receives ISO 13485:2016 Quality Certification

April 6, 2023, MILFORD, Mass. – Boston BioProducts, a longstanding manufacturer of fundamental reagents for the life sciences, announced that its quality management system (QMS) has achieved ISO 13485:2016 certification from TÜV SÜD America for the medical device manufacturing and supply of buffers, solutions, media, and reagents serving research, diagnostics, and therapeutics applications. Achieving this certification signifies Boston BioProducts’ commitment to high-quality standards across the entire reagent manufacturing process.

U.S. FDA Grants RMAT Designation to Intellia Therapeutics for NTLA-2002 in Treatment of Hereditary Angioedema

CAMBRIDGE, Mass. – Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, announced that the U.S. FDA granted RMAT designation to NTLA-2002 for the treatment of hereditary angioedema (HAE). NTLA-2002 is an in vivo CRISPR-based investigational therapy designed to inactivate the target gene, kallikrein B1 (KLKB1), to potentially prevent life-threatening swelling attacks in people with HAE.

Tempo Bioscience Expands Human Liver Models for Toxicity Evaluation and Disease Modeling

SAN FRANCISCO, CA - Tempo Bioscience is the sole manufacturer of human iPSC-derived cell types that are engineered using non-viral, nucleic-acids-free, serum-free, and feeder-free technologies. Tempo is committed to advancing technologies that focus on disease modeling and drug safety evaluations using advanced human iPSC-derived cell models in 2D, as well as in 3D as spheroids or organoids. Tempo’s patient-relevant cell models aim to improve drug efficacy evaluations and safety assessments during drug development.

What Is An RMAT? List of Publicly Announced RMAT Designations (75)

To date, what number of U.S. FDA approved RMATs have been issued and to whom have they been awarded? The answer is that 75 RMAT designations have been publicly announced by biotech and pharma companies. However, the FDA states it has received 219 requests and issued 86, which means that a handful are not yet public knowledge. Therefore, a few companies are operating in stealth mode with regard to their RMAT designations and approximately 39% of RMAT applications get approved (86 approvals / 219 applications = 39.3%).

The History of Cultured Meat and Where We're At Today

Cultured meat appears to have been first mentioned in 1897 within a science fiction novel titled Auf Zwei Planeten. In the late 1990s, Willem van Eelen was the first applicant to file a patent for a cultured meat manufacturing method. It seems that the first cultured meat eaten by humans was by the efforts of the bio-artist, Oron Catts. In his 2003 project, Disembodied Cuisine, Oron Catts obtained cultured meat from a frog and served tiny frog steaks during a dinner at a museum in Nantes, France. The general public became aware of cultured meat only after a TV show aired in 2013 in London in which cultured meat was tasted by two journalists.

Global Database of Cultured ("Clean") Meat Companies, 2023

Just released, this global database reveals the identities of all known cultured meat companies worldwide. Cultured meat refers to lab-grown meat created using cell culture techniques. It is produced by growing stem cells collected from cattle, chicken, pigs, fish, and lamb, as well as other types of livestock and seafood. In addition to meat production, cultured meat techniques can be used to ethically manufacture animal byproducts, such as leather, fur, milk, and hen-free egg whites, for example For a limited-time only, you can claim it for 50% off.

[NEW] Global Induced Pluripotent Stem Cell (iPSC) Industry Report - Market Size, Trends, and Forecasts, 2023

In addition to the iPSC cell therapy developers, there are an ever-growing number of market competitors who are commercializing iPSC-derived products for use across a diverse range of applications. These applications include drug development and discovery, disease modeling, toxicology testing, and personalized medicine, as well as tissue engineering, 3D bioprinting, and clean meat production. This report reveals all major market competitors worldwide and presents a market size breakdown for iPSCs by Application, Technology, Cell Type, and Geography (North America, Europe, Asia/Pacific, and RoW), with projections through 2030.

To access other market insights about CAR-T cell therapy, MSCs, iPSCs, cord blood, and beyond, explore the BioInformant Shop.

*Want to advertise in this newsletter? Contact us at Info@BioInformant.com.